Literature DB >> 4159034

GM and INV factors in subclasses of human IgG.

W D Terry, J L Fahley, A G Steinberg.   

Abstract

Human G myeloma (7S gamma(2)-myeloma) proteins were investigated for relationships between Gm and Inv genetic factors and the different antigenic types of heavy polypeptide chains (gamma-chains) and light polypeptide chains. Myeloma proteins were isolated from the sera of 1 Chinese, 60 white and 28 Negro individuals. These 89 proteins were tested for eight Gm factors [Gm(a), Gm(x), Gm(b(2)), Gm(f), Gm(b(1)), Gm(b(3)), Gm(b(4)), and Gm(c)], and two Inv factors [Inv(l) and Inv(b)]. Results of the tests were correlated with the four gamma-chain subclasses (gamma(2a), gamma(2b), gamma(2c) and gamma(2d)) and the two types of light polypeptide chains, kappa-chains (type K or I) and lambda-chains (type L or II) found in human IgG molecules. 1. Gm factors were limited to myeloma proteins with heavy polypeptide chains of the gamma(2b)- and gamma(2c)-subclasses. No Gm factors were detected on gamma(2a)- and gamma(2d)-myeloma proteins or on a "heavy-chain" disease protein of subclass gamma(2d). 2. gamma(2b)-Proteins were positive for at least one Gm factor and were either Gm(a+), Gm(a + x+), or Gm(b(2)+ f+). 3. gamma(2c)-Myeloma proteins, and one gamma(2c)-"heavy-chain" disease protein, were positive for at least one Gm factor and contained various combinations of factors Gm(b(1)), (b(2)), (b(4)), and (c). Myeloma proteins from 3 Negroes were included in this group. 4. Inv factors (l) and (b) were limited to myeloma proteins with kappa-light polypeptide chains. These Inv factors were not detected on proteins with lambda-light polypeptide chains. 5. Most (70 per cent) of the gamma(2b)- and gamma(2c)-proteins with kappa-chains were Inv(l+) or Inv(b+). None of the gamma(2a)- or gamma(2d)-proteins with kappa-chains, however, contained these Inv factors.

Entities:  

Mesh:

Substances:

Year:  1965        PMID: 4159034      PMCID: PMC2138098          DOI: 10.1084/jem.122.6.1087

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  28 in total

1.  STRUCTURAL STUDIES OF THE IMMUNOGLOBULINS. I. THE TRYPTIC PEPTIDES OF BENCE-JONES PROTEINS.

Authors:  F W PUTNAM; C W EASLEY
Journal:  J Biol Chem       Date:  1965-04       Impact factor: 5.157

2.  Localization of two genetic factors to different areas of gamma-globulin molecules.

Authors:  M HARBOE; C K OSTERLAND; H G KUNKEL
Journal:  Science       Date:  1962-06-15       Impact factor: 47.728

3.  A new human gamma globulin factor determined by an allele at the Inv locus.

Authors:  A G STEINBERG; J A WILSON; S LANSET
Journal:  Vox Sang       Date:  1962       Impact factor: 2.144

4.  On structural and functional relations between antibodies and proteins of the gamma-system.

Authors:  G M EDELMAN; B BENACERRAF
Journal:  Proc Natl Acad Sci U S A       Date:  1962-06-15       Impact factor: 11.205

5.  Dissociation of animal 7 S gamma-globulins by cleavage of disulfide bonds.

Authors:  F FRANEK
Journal:  Biochem Biophys Res Commun       Date:  1961-01-25       Impact factor: 3.575

6.  Hereditary serological human serum groups.

Authors:  R GRUBB; A B LAURELL
Journal:  Acta Pathol Microbiol Scand       Date:  1956

7.  SUBCLASSES OF HUMAN GAMMA-2-GLOBULIN BASED ON DIFFERENCES IN THE HEAVY POLYPEPTIDE CHAINS.

Authors:  W D TERRY; J L FAHEY
Journal:  Science       Date:  1964-10-16       Impact factor: 47.728

8.  Genetic characters of human gamma-globulins in myeloma proteins.

Authors:  M HARBOE; C K OSTERLAND; M MANNIK; H G KUNKEL
Journal:  J Exp Med       Date:  1962-11-01       Impact factor: 14.307

9.  TWO MAJOR TYPES OF NORMAL 7S gamma-GLOBULIN.

Authors:  M Mannik; H G Kunkel
Journal:  J Exp Med       Date:  1963-01-31       Impact factor: 14.307

10.  CLASSIFICATION OF MYELOMA PROTEINS, BENCE JONES PROTEINS, AND MACROGLOBULINS INTO TWO GROUPS ON THE BASIS OF COMMON ANTIGENIC CHARACTERS.

Authors:  M Mannik; H G Kunkel
Journal:  J Exp Med       Date:  1962-11-30       Impact factor: 14.307

View more
  21 in total

1.  The C-terminal sequences of the heavy chains of human immunoglobulin G myeloma proteins of differing isotopes and allotypes.

Authors:  J W Prahl
Journal:  Biochem J       Date:  1967-12       Impact factor: 3.857

2.  Km typing with PCR: application to population screening.

Authors:  J H Kurth; A M Bowcock; H A Erlich; S Nevo; L L Cavalli-Sforza
Journal:  Am J Hum Genet       Date:  1991-03       Impact factor: 11.025

3.  Compleat immunology: science or septophrenia?

Authors:  H H Fudenberg
Journal:  Clin Exp Immunol       Date:  1967-01       Impact factor: 4.330

4.  The disulphide bridges of immunoglobulin kappa-chains.

Authors:  C Milstein
Journal:  Biochem J       Date:  1966-11       Impact factor: 3.857

5.  Qualitative and quantitative studies on IgG2 globulins in individual human sera with an antiserum capable of differentiating between Gm(n+) and Gm(n-) proteins.

Authors:  M van der Giessen; W Freyee; E Rossouw; E van Loghem
Journal:  Clin Exp Immunol       Date:  1973-05       Impact factor: 4.330

6.  Biosynthetic and structural studies of a heavy chain disease protein.

Authors:  D Ein; D N Buell; J L Fahey
Journal:  J Clin Invest       Date:  1969-04       Impact factor: 14.808

Review 7.  [Bence Jones proteins].

Authors:  M Eulitz
Journal:  Blut       Date:  1969-02

8.  Human immunoglobulin subclasses. Partial amino acid sequence of the constant region of a gamma 4 chain.

Authors:  J R Pink; S H Buttery; G M De Vries; C Milstein
Journal:  Biochem J       Date:  1970-03       Impact factor: 3.857

9.  Immunoglobulins in Jamaicans and Nigerians with immunogenetic typing of myeloma and lymphoma in Jamaicans.

Authors:  H McFarlane; A Talerman; A G Steinberg
Journal:  J Clin Pathol       Date:  1970-03       Impact factor: 3.411

10.  The renal handling of low molecular weight proteins. II. Disorders of serum protein catabolism in patients with tubular proteinuria, the nephrotic syndrome, or uremia.

Authors:  T A Waldmann; W Strober; R P Mogielnicki
Journal:  J Clin Invest       Date:  1972-08       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.